Search

Additional file 2. Frequency of mutated genes in risk groups and list of risk group associated pathway.

Additional file 1. Frequency of variants and mutated genes.

Additional file 5. Result of GSVA analysis.

Additional file 3. Sequence of recurrent fusions and expression profile of genes having fusions.

Additional file 1: Table S1. Evaluation of 12 candidate variants from the discovery cohort (N = 188) by using the replication cohort (N = 52) for both NUDT15 and TPMT wild-type subjects. Table S2. Evaluation of frequency distributions of CRIM1 rs3821169 genotypes across different cutoffs of the last-cycle 6-mercaptopurine dose intensity percentage tolerated by pediatric acute lymphoblastic leukemia subjects. Figure S1. Improvement of prediction accuracy of GVBNUDT15,TPMT for thiopurine toxicity after controlling for homozygote carriers of CRIM1 rs3821169. Figure S2. Prediction accuracies of GVBNUDT15,CRIM1 and GVBTPMT,CRIM1 for thiopurine toxicity in pediatric ALL subjects. Figure S3. Prediction accuracies of GVBNUDT15,TPMT,CRIM1 for thiopurine toxicity in pediatric ALL subjects. Figure S4. Prediction accuracy of GVBCRIM1 for thiopurine toxicity in pediatric ALL subjects. Figure S5. Prediction accuracy of GVBNUDT15 for thiopurine toxicity in pediatric ALL subjects. Figure S6. Prediction accuracy of GVBTPMT for thiopurine toxicity in pediatric ALL subjects. Figure S7. Youden’s index to find the optimal thresholds for GVBNUDT15,TPMT and GVBNUDT15,TPMT,CRIM1. Figure S8. Comparison of CRIM1 mRNA expression levels of rs3821169 carriers and noncarriers in hematopoietic and lymphoid tissue. Figure S9. Results of Sanger sequencing for the two NUDT15 variants identified via whole exome sequencing.

Additional file 4. Result of DEG analysis.

Additional file 6. Result of Mutational signature analysis.

This multicenter, prospective trial was conducted to develop an effective and safe reinduction regimen for marrow-relapsed pediatric acute lymphoblastic leukemia (ALL) by modifying the dose of idarubicin. Between 2006 and 2009, the trial accrued 44 patients, 1 to 21 years old with first marrow-relapsed ALL. The reinduction regimen comprised prednisolone, vincristine, L-asparaginase, and idarubicin (10 mg/m2/week). The idarubicin dose was adjusted according to the degree of myelosuppression. The second complete remission (CR2) rate was 72.7%, obtained by 54.2% of patients with early relapse < 24 months after initial diagnosis and 95.0% of those with late relapse (P = 0.002). Five patients entered remission with extended treatment, resulting in a final CR2 rate of 84.1%. The CR2 rate was not significantly different according to the idarubicin dose. The induction death rate was 2.3% (1/44). The 5-year event-free and overall survival rates were 22.2% ± 6.4% and 27.3% ± 6.7% for all patients, 4.2% ± 4.1% and 8.3% ± 5.6% for early relapsers, and 43.8% ± 11.4% and 50.0% ± 11.2% for late relapsers, respectively. Early relapse and slow response to reinduction chemotherapy were predictors of poor outcomes. In conclusion, a modified dose of idarubicin was effectively incorporated into the reinduction regimen for late marrow-relapsed ALL with a low toxic death rate. However, the CR2 rate for early relapsers was suboptimal, and the second remission was not durable in most patients., Graphical Abstract

Objectives: B. cereus has been reported as a cause of serious nosocomial infection in hematology-oncology patients. In our pediatric cancer ward, only one or two episodes of B. cereus associated bacteremia have been observed. However, a sudden rise in number of patients with bacteremia caused by B. [for full text, please go to the a.m. URL], 18th Symposium on Infections in the Immunocompromised Host